SCHEMBL3759709

SCHEMBL3759709

CNc1cn[c]c(-c2ccccc2)c1N1CCC1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.32
HTR3A P46098 1/20 0.32
ALDH1A1 P00352 4/20 0.31
KMT2A Q03164 2/20 0.31
KDM4E B2RXH2 2/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
BRD4 O60885 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
MEN1 O00255 1/20 0.31
ADORA2A P29274 1/20 0.30
ADORA1 P30542 1/20 0.30
HSD17B10 Q99714 2/20 0.30
MAT2A P31153 1/20 0.30
USP2 O75604 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C9 P11712 1/20 0.30
ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3759744 0.96 NPY5R (0.36) NPY5RALDH1A1KMT2AKDM4ENPC1
SCHEMBL3763028 0.78 LMNA (0.35) ALDH1A1KMT2AKDM4ENPC1RAB9A
SCHEMBL3760043 0.76 SMN1; SMN2 (0.44) KMT2ANPC1RAB9AMEN1USP2
SCHEMBL3760258 0.75 HTT (0.38) ALDH1A1KMT2AKDM4ENPC1RAB9A
SCHEMBL3757772 0.74 HSD17B10 (0.40) ALDH1A1KMT2AKDM4ENPC1RAB9A
SCHEMBL3757720 0.74 TDO2 (0.34) ALDH1A1KDM4EBRD4TDP1L3MBTL1
SCHEMBL3751655 0.73 KMT2A (0.45) ALDH1A1KMT2ANPC1RAB9AMEN1
SCHEMBL3763874 0.72 KMT2A (0.44) ALDH1A1KMT2ANPC1RAB9AMEN1
SCHEMBL3751377 0.70 NPY5R (0.41) NPY5RHTR3AALDH1A1KMT2AKDM4E
SCHEMBL3998045 0.69 ADRB1 (0.43) NPY5RHTR3AALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA NPY5R 4725/4885HTR3A 1897/4885ALDH1A1 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.